Praxis Precision Medicines, Inc.

PRAX Healthcare Biotechnology

Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.

Revenue
+1,349.1%
EPS
+13.3%
Free cash flow
−43.5%

Quarter to June 2026, against a year earlier

276.13 13.54 +5.16%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−24.3×
Dividend yield
—
F-score
n/a
Altman Z
19.09
Beneish M
n/a
Dividend safety
n/a

Praxis Precision Medicines, Inc. 10-Q filed Aug 6, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 8:32 AM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 4, 2025: 19 added · 25 removed · 42 modified; 9 with only figures updated; 5 moved without change